- Tous > Medicine Access and Rational Use > Pricing
- Tous > Medicine Access and Rational Use > Supply Management
- Tous > Public Health, Innovation, Intellectual Property and Trade > Intellectual Property (IP) and Trade
- Mots-clés > access to antiretrovirals (ARVs)
- Mots-clés > ARV management policy/practices
- Mots-clés > Intellectual Property Rights (IPR)
- Mots-clés > licensing system
- Mots-clés > patent and licensing status - ARV
- Mots-clés > patent system
- Mots-clés > patentability criteria - policy options
- Mots-clés > patents - examination of pharmaceutical patents
- Mots-clés > procurement of antiretrovirals
(2014; 34 pages)
The report provides an overview of the patent landscape with respect to a select number of antiretroviral (ARV) medicines in developing countries as of April 2014. The focus is primarily on those ARVs that are recommended by the World Health Organization (WHO) as well as new ARVs that have either recently obtained regulatory approval or are in phase III clinical trials.
Part 1 provides a brief introduction to patents and licences and their effect on the market for ARVs. It introduces key concepts that will facilitate an understanding of the report. It also explains which data sources were used for the report and notes a number of disclaimers with regard to the information contained in the report.
Part 2 is the core of the report. It outlines the patent status and licensing status of each ARV in the 81 developing countries for which data are available. For each ARV the report indicates whether that ARV is included in fixeddose combinations for which there may be patents. General conclusions are drawn in light of the data. The key purpose is to provide an overview of the patent landscape for each ARV and, in particular, to show in which countries market competition for a given ARV is possible in view of existing patents and licences.
Annex I is a summary table that provides a “snapshot” of ARV patents and licences in developing countries.
Annex II provides an overview of patents with respect to selected fixed-dose combinations.
Annex III summarizes the information that is currently publicly available on existing voluntary licences.